Table 1.
Description of the 28 subjects included in this study.
| Subject ID | Plasma | ABC-Amyloid | ABC-Braak | ABC-CERAD | ABC-burden | Age at death | ApoE | Neuropathology notes | Cerebrovascular pathology |
|---|---|---|---|---|---|---|---|---|---|
| AD01 | 2 | 3 | 2 | Intermediate | 80–90 | e2/e3 | |||
| AD02 | 2 | 3 | 2 | Intermediate | 80–90 | e3/e3 | |||
| AD03 | 3 | 3 | 1 | Intermediate | >90 | e4/e3 | |||
| AD04 | 2 | 3 | 2 | Intermediate | 80–90 | e3/e3 | CVD, INF | ||
| AD05 | 2 | 3 | 2 | Intermediate | 80–90 | e3/e3 | |||
| AD06 | 2 | 3 | 2 | Intermediate | 80–90 | e3/e3 | |||
| AD07 | * | 3 | 3 | 3 | High | 70–80 | e4/e4 | ||
| AD08 | * | 3 | 3 | 3 | High | 60–70 | e4/e3 | ||
| AD09 | * | 3 | 3 | 2 | High | >90 | e4/e3 | CVD, CAA | |
| AD10 | * | 3 | 3 | 2 | High | 80–90 | e4/e3 | Hippocampal Sclerosis | |
| AD11 | * | 3 | 3 | 3 | High | 80–90 | e4/e4 | ||
| AD12 | 3 | 3 | 3 | High | 70–80 | e4/e3 | CVD | ||
| AD13 | * | 3 | 3 | 3 | High | 80–90 | e4/e3 | ||
| AD14 | * | 3 | 3 | 2 | High | 80–90 | e4/e3 | CVD, CAA | |
| AD15 | * | 3 | 3 | 3 | High | 60–70 | e4/e3 | CAA | |
| AD16 | * | 3 | 3 | 2 | High | >90 | e2/e3 | CVD, CAA | |
| CTRL01 | 0 | 0 | 0 | Not AD | 50–60 | e3/e3 | |||
| CTRL02 | * | 0 | 0 | 0 | Not AD | >90 | e3/e3 | PSP | |
| CTRL03 | 0 | 1 | 0 | Not AD | 80–90 | e3/e3 | |||
| CTRL04 | 0 | 1 | 1 | Not AD | >90 | e2/e3 | |||
| CTRL05 | 0 | 1 | 1 | Not AD | >90 | e3/e3 | CVD | ||
| CTRL06 | * | 0 | 1 | 0 | Not AD | >90 | e3/e3 | CVD, INF | |
| CTRL07 | 0 | 1 | 0 | Not AD | >90 | e3/e3 | |||
| CTRL08 | 0 | 1 | 0 | Not AD | 70–80 | e3/e3 | |||
| CTRL09 | * | 0 | 1 | 0 | Not AD | >90 | e3/e3 | INF | |
| CTRL10 | 2 | 1 | 1 | Low | >90 | e3/e3 | CVD | ||
| CTRL11 | 1 | 1 | 1 | Low | 70–80 | e3/e3 | CAA | ||
| CTRL12 | * | 1 | 1 | 0 | Low | >90 | e3/e3 | LBD, PART | CVD, Arteriolosclerosis |
These 28 subjects were selected for microvascular gene expression analysis. Age at death is binned by decade per journal policy. An asterisk in the “Plasma” column indicates the subject also had longitudinal plasma collection for protein quantification. PSP, progressive supranuclear palsy; LBD, Lewy-body dementia; PART, primary age-related tauopathy; CVD, cerebrovascular disease; INF, infarcts; CAA, cerebral amyloid angiopathy.